UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED):
May 11, 2004
GILEAD SCIENCES, INC.
(Exact
name of registrant as specified in its charter)
|
DELAWARE |
|
0-19731 |
|
94-3047598 |
|
(State
or other jurisdiction of |
|
(Commission File Number) |
|
(I.R.S.
Employer |
|
|
|
|
|
|
|
333 LAKESIDE DRIVE, FOSTER CITY, CALIFORNIA |
||||
|
(Address of principal executive offices) |
||||
|
|
|
|
|
|
|
94404 |
||||
|
(Zip Code) |
||||
|
|
|
|
|
|
|
(650) 574-3000 |
||||
|
(Registrant’s telephone number, including area code) |
||||
ITEM 5. OTHER EVENTS AND REGULATION FD DISCLOSURE.
On May 3, 2004, Gilead Sciences, Inc., a Delaware corporation, issued a press release announcing that it has implemented a stock trading program in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. A copy of the press release is filed as Exhibit 99.1 to this report. Paul Berg, PhD, a member of Gilead’s Board of Directors, has established a stock trading plan in accordance with Gilead’s stock trading program under Rule 10b5-1. Other participating Gilead executives and Board members may establish pre-arranged stock trading plans to buy or sell pre-determined amounts of Gilead stock over time under Gilead’s 10b5-1 stock trading program.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS
(c) Exhibits
|
Exhibit |
|
Description |
|
99.1 |
|
Press Release, issued by Gilead Sciences, Inc. on May 3, 2004 |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
GILEAD SCIENCES, INC. |
|
|
|
(registrant) |
|
|
|
|
|
|
|
/s/ John F. Milligan |
|
|
|
John F. Milligan |
|
|
|
Executive Vice President and |
|
|
|
Chief Financial Officer |
|
|
|
|
|
|
Date: May 11, 2004 |
|
|
3
Exhibit Index
|
Exhibit |
|
Description |
|
99.1 |
|
Press Release, issued by Gilead Sciences, Inc. on May 3, 2004 |
4